Sharekhan has given Buy recommendation for Abbott India with a target price of Rs. 22,780 in its research report issued on Dec 13, 2021

Sharekhan’s research report on Abbott India

Abbott India Limiteds (Abbott) revenues and PAT are expected to grow in double digits over next two years, led by healthy growth in IPM, presence in high-growth therapy areas and strong performance of top brands. Sustained growth and leadership from existing brands, product portfolio expansion, efforts to improve the reach and penetration would be the key drivers. Leveraging the digital platform to cost-effectively improve geographic penetration also bodes well.

Outlook

Given the strong growth prospects & financials and a sturdy dividend payout we re-iterate our Buy recommendation on Abbott with an unchanged PT of Rs. 22,780.

Leave a Reply

Your email address will not be published.